NewAmsterdam Pharma
NAMS
22.13
-0.14
-0.63%
NewAmsterdam Pharma
US · NAMS
#2583 by market cap
Listed 1970
22.13
-0.14
-0.63%
Live - 5344 symbols - heartbeat 25s ago
· 2026-10-08 05:13
Pre-market
21.98
-0.69%
After-hours
22.52
+1.76%
Overnight
22.09
-0.18%
- Market cap
- 2.65B
- P/E (TTM)i
- -10.25
- P/Bi
- 4.19
- EPSi
- -1.72
- Div yieldi
- 0.00%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on NAMS?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
52.75 +138.4%
Price target rangecurrent 22.13
Low42.00
Avg52.75
High60.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | RBC Capital | -- | BUY | 42.00 |
| 2026-10-02 | Wells Fargo | -- | BUY | 55.00 |
| 2026-09-29 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-09-22 | Truist Financial | -- | BUY | 57.00 |
| 2026-09-21 | BMO Capital | -- | BUY | 58.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-09-18 | William Blair | -- | BUY | -- |
| 2026-09-08 | Truist Financial | -- | BUY | -- |
| 2026-09-08 | Stifel | -- | BUY | 50.00 |
| 2026-09-08 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-08-07 | Needham | -- | BUY | 48.00 |
| 2026-08-06 | William Blair | -- | BUY | -- |
| 2026-08-06 | Truist Financial | -- | BUY | -- |
| 2026-08-06 | Stifel | -- | BUY | 50.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-08-05 | BMO Capital | -- | BUY | 58.00 |
| 2026-08-05 | RBC Capital | -- | BUY | 50.00 |
| 2026-08-04 | Piper Sandler | -- | BUY | 60.00 |
| 2026-07-27 | Truist Financial | -- | BUY | 57.00 |
| 2026-07-24 | William Blair | -- | BUY | -- |
| 2026-07-24 | Needham | -- | BUY | 48.00 |
| 2026-07-24 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-07-21 | BMO Capital | -- | BUY | 58.00 |
| 2026-07-15 | H.C. Wainwright | -- | BUY | 52.00 |
| 2026-06-30 | RBC Capital | -- | BUY | 51.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 05:13:58 · For reference only, not investment advice and not tailored to your situation.